Le Lézard
Classified in: Science and technology, Business
Subjects: CCA, ACC

Stockholm IT Ventures Holds Business Update Webinar


STOCKHOLM, Dec. 6, 2018 /PRNewswire/ -- Stockholm IT Ventures AB (Frankfurt Stock Exchange: SVAB - ISIN SE 0006027546) will host a webinar presenting its updated product- and rollout-strategy for 2019.

The webinar will be hosted by CEO Anthony Norman on Tuesday December 11th,  2018, at 14:00 CET (Stockholm) time.

The management will present additional outlines on the company's digital banking strategy, following its recent acquisitions in the segment.

To participate, kindly register at http://stockholmit.co/webinar

Media Contact: Stockholm IT Ventures AB, Anthony Norman, [email protected]

This information was brought to you by Cision http://news.cision.com

 


These press releases may also interest you

at 01:05
Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensorstm currently deployed in over 500 million devices, is shipping its AI Virtual Proximity Sensortm INNER BEAUTY® on vivo's newly announced iQOO Z9...

at 00:50
OKX, a leading Web3 technology company, has issued updates for April 25, 2024. OKX Wallet Now Integrated with XION, a User-First ...

at 00:30
Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), is thrilled to announce its continued partnership with the Tourism Authority of Thailand (TAT) for the fourth consecutive year, showcasing the unparalleled beauty...

at 00:30
ENOC Group, a leading integrated global energy player, has appointed the innovative technology loyalty partner, Loyyal, to integrate Access Point, their self-service platform, into the Group's rewards programme. This move will revolutionize the 'YES'...

at 00:05
Systal Technology Solutions, a global managed network, cloud, and security transformation specialist, today announces the opening of its new Network Operations Center (NOC) in Tampa, Florida. This marks the latest milestone in Systal's recent growth...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...



News published on and distributed by: